AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 33842519 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychobiotic Supplementation of PS128
Number of subjects: 0
Study 33842870 — intervention group
Group type: EXPERIMENTAL
Intervention: ASP0113 (5 mg/mL, 1 mL, five injections)
Number of subjects: 501
Study 33842870 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 501
Study 33842889 — intervention group
Group type: EXPERIMENTAL
Intervention: Preprocessing of radiomics features using PyRadiomics
Number of subjects: 48
Study 33842889 — intervention group
Group type: EXPERIMENTAL
Intervention: Normalization and intensity quantization
Number of subjects: 48
Study 33842908 — intervention group
Group type: EXPERIMENTAL
Intervention: UNI91104 (inhaled and intranasal niclosamide)
Number of subjects: 34
Study 33842908 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study 33843247 — intervention group
Group type: EXPERIMENTAL
Intervention: hs-CRP (high-sensitivity C-reactive protein)
Number of subjects: 3784
Study 33843247 — intervention group
Group type: EXPERIMENTAL
Intervention: Interleukin-6
Number of subjects: 3784
Study 33843247 — intervention group
Group type: EXPERIMENTAL
Intervention: Inflammation score
Number of subjects: 3784
Study 33843258 — intervention group
Group type: EXPERIMENTAL
Intervention: Consensus decision-making on continuation and regimen of preoperative antiplatelet therapy (APT)
Number of subjects: 3582
Study 33843258 — intervention group
Group type: COMPARATOR
Intervention: Arbitrary APT not based on a consensus decision
Number of subjects: 3582
Study 33843258 — intervention group
Group type: COMPARATOR
Intervention: Arbitrary APT
Number of subjects: 3582
Study 33843594 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical Decision Support with Patient Education (CDS-E)
Number of subjects: 51
Study 33843594 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical Decision Support without Patient Education (CDS)
Number of subjects: 51
Study 33843594 — intervention group
Group type: COMPARATOR
Intervention: Standard Practice
Number of subjects: 51
Study 33843594 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 51
Study 33843599 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based dialectical behavior therapy (DBT) skills site with secure message coaching; no specific dosage or duration mentioned.
Number of subjects: 60
Study 33843599 — intervention group
Group type: EXPERIMENTAL
Intervention: DBT skills website users
Number of subjects: 60
Study 33843785 — intervention group
Group type: EXPERIMENTAL
Intervention: IBS-D
Number of subjects: 42
Study 33843785 — intervention group
Group type: EXPERIMENTAL
Intervention: IBS-C
Number of subjects: 42
Study 33843785 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 42
Study 33843815 — intervention group
Group type: EXPERIMENTAL
Intervention: Bone marrow transplantation with myeloablative conditioning (thiotepa, busulfan, and cyclophosphamide) without radiation, followed by 12 post-transplant lumbar punctures with intrathecal cytarabine.
Number of subjects: 2
Study 33843946 — intervention group
Group type: EXPERIMENTAL
Intervention: Time-limited trials (TLTs) as the default care-planning approach
Number of subjects: 209
Study 33844007 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine
Number of subjects: 116
Study 33844007 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 116
Study 33844036 — intervention group
Group type: EXPERIMENTAL
Intervention: Study period (March-April 2020)
Number of subjects: 532
Study 33844036 — intervention group
Group type: COMPARATOR
Intervention: Control period (2018-2019)
Number of subjects: 532
Study 33844429 — intervention group
Group type: EXPERIMENTAL
Intervention: Blinatumomab
Number of subjects: 0
Study 33844595 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab (2 mg/kg or 200 mg every 3 weeks)
Number of subjects: 28
Study 33844623 — intervention group
Group type: EXPERIMENTAL
Intervention: 9vHPV vaccine (three doses: Day 1, Month 2, Month 6)
Number of subjects: 201
Study 33844938 — intervention group
Group type: EXPERIMENTAL
Intervention: Social Media Support from Friends
Number of subjects: 0
Study 33844938 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 33844998 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled budesonide
Number of subjects: 0
Study 33844998 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 33845032 — intervention group
Group type: EXPERIMENTAL
Intervention: Renin-Angiotensin system inhibitors (RASi)
Number of subjects: 6503
Study 33845032 — intervention group
Group type: COMPARATOR
Intervention: No RASi
Number of subjects: 6503
Study 33845259 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-transplantation bendamustine (PTB) at doses of 140 mg/m², 100 mg/m², and 70 mg/m²
Number of subjects: 0
Study 33845259 — intervention group
Group type: COMPARATOR
Intervention: Post-transplantation cyclophosphamide
Number of subjects: 0
Study 33845648 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified Chinese Autism Spectrum Rating Scale
Number of subjects: 2013
Study 33845785 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk assessment framework for trial activities
Number of subjects: 0
Study 33845785 — intervention group
Group type: EXPERIMENTAL
Intervention: Guidance on protective measures
Number of subjects: 0
Study 33845785 — intervention group
Group type: EXPERIMENTAL
Intervention: Assessment of risk based on staff proximity, exposure time, and potential viral aerosolization
Number of subjects: 0
Study 33845865 — intervention group
Group type: EXPERIMENTAL
Intervention: Externally stented SVG
Number of subjects: 102
Study 33845865 — intervention group
Group type: COMPARATOR
Intervention: Non-stented SVG
Number of subjects: 102
Study 33845893 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-term (ST) metformin withdrawal
Number of subjects: 44
Study 33845893 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-term (LT) metformin withdrawal
Number of subjects: 44
Study 33845893 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (ST and LT)
Number of subjects: 44
Study 33845905 — intervention group
Group type: EXPERIMENTAL
Intervention: Dalpiciclib 100 mg, 125 mg, and 150 mg
Number of subjects: 40
Study 33845905 — intervention group
Group type: EXPERIMENTAL
Intervention: Dalpiciclib
Number of subjects: 40
Study 33845905 — intervention group
Group type: EXPERIMENTAL
Intervention: Dalpiciclib 125 mg and 150 mg cohorts
Number of subjects: 40
Study 33845905 — intervention group
Group type: EXPERIMENTAL
Intervention: Dalpiciclib 150 mg cohort
Number of subjects: 40
Study 33846069 — intervention group
Group type: EXPERIMENTAL
Intervention: Grey-scale ultrasonography
Number of subjects: 28
Study 33846069 — intervention group
Group type: EXPERIMENTAL
Intervention: Shear wave elastography (SWE)
Number of subjects: 28
Study 33846069 — intervention group
Group type: EXPERIMENTAL
Intervention: FibroTest™ score
Number of subjects: 28
Study 33846069 — intervention group
Group type: EXPERIMENTAL
Intervention: ActiTest™ score
Number of subjects: 28
Study 33846084 — intervention group
Group type: EXPERIMENTAL
Intervention: cSAA assay measuring serum anticholinergic activity
Number of subjects: 311
Study 33846084 — intervention group
Group type: EXPERIMENTAL
Intervention: cSAA assay
Number of subjects: 311
Study 33846112 — intervention group
Group type: EXPERIMENTAL
Intervention: MRI-targeted biopsy (TBx)
Number of subjects: 0
Study 33846112 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined biopsy (TBx plus SBx)
Number of subjects: 0
Study 33846112 — intervention group
Group type: COMPARATOR
Intervention: Systematic biopsy (SBx)
Number of subjects: 0
Study 33846719 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent preventative treatment in pregnancy with sulfadoxine-pyrimethamine (IPTp-SP)
Number of subjects: 1850
Study 33846719 — intervention group
Group type: EXPERIMENTAL
Intervention: Malaria infection
Number of subjects: 1850
Study 33846719 — intervention group
Group type: EXPERIMENTAL
Intervention: Malaria treatment after diagnosis alongside IPTp-SP
Number of subjects: 1850
Study 33846844 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 MBq of a novel theranostic PET radiopharmaceutical
Number of subjects: 9
Study 33846843 — intervention group
Group type: EXPERIMENTAL
Intervention: Breast MRI
Number of subjects: 102
Study 33846843 — intervention group
Group type: COMPARATOR
Intervention: Normal MRI (no suspicious enhancement)
Number of subjects: 102
Study 33846845 — intervention group
Group type: EXPERIMENTAL
Intervention: PSMA PET
Number of subjects: 55
Study 33846845 — intervention group
Group type: EXPERIMENTAL
Intervention: mpMR
Number of subjects: 55
Study 33846845 — intervention group
Group type: EXPERIMENTAL
Intervention: PET/MR
Number of subjects: 55
Study 33846845 — intervention group
Group type: EXPERIMENTAL
Intervention: PET
Number of subjects: 55
Study 33846850 — intervention group
Group type: EXPERIMENTAL
Intervention: Stapedotomy
Number of subjects: 25
Study 33847032 — intervention group
Group type: EXPERIMENTAL
Intervention: Support from parents and 'other important people' (e.g., friends, spouses)
Number of subjects: 49
Study 33847032 — intervention group
Group type: EXPERIMENTAL
Intervention: Support from siblings with SCD
Number of subjects: 49
Study 33847257 — intervention group
Group type: EXPERIMENTAL
Intervention: Low serum retinol (LSR) defined as serum retinol ≤20 µg/dl
Number of subjects: 803
Study 33847257 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 803
Study 33847298 — intervention group
Group type: EXPERIMENTAL
Intervention: Postvaccine period (2015-2016)
Number of subjects: 479
Study 33847298 — intervention group
Group type: COMPARATOR
Intervention: Prevaccine period (2007-2008)
Number of subjects: 479
Study 33847298 — intervention group
Group type: EXPERIMENTAL
Intervention: G2P[8], G1P[8], G4P[4], G9P[8], and G8P[8]
Number of subjects: 479
Study 33847526 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 33847588 — intervention group
Group type: EXPERIMENTAL
Intervention: Tech support plus health coaching intervention group
Number of subjects: 54
Study 33847588 — intervention group
Group type: EXPERIMENTAL
Intervention: Tech support intervention group
Number of subjects: 54
Study 33847588 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control group
Number of subjects: 54
Study 33847874 — intervention group
Group type: EXPERIMENTAL
Intervention: Crizotinib 250 mg twice daily
Number of subjects: 9
Study 33848093 — intervention group
Group type: EXPERIMENTAL
Intervention: Pediatric heat illness treatment
Number of subjects: 0
Study 33848093 — intervention group
Group type: EXPERIMENTAL
Intervention: Adolescent athletes undergoing high-intensity training
Number of subjects: 0
Study 33848093 — intervention group
Group type: EXPERIMENTAL
Intervention: Children trapped in closed spaces
Number of subjects: 0
Study 33848093 — intervention group
Group type: EXPERIMENTAL
Intervention: Extreme temperatures and radiant heat exposure
Number of subjects: 0
Study 33848199 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment-related changes in left atrial structure, specific details not available.
Number of subjects: 0
Study 33848258 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical therapy, balloon pulmonary angioplasty, and medical therapy (details collected at enrollment and follow-up)
Number of subjects: 750
Study 33848258 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality of life surveys administered at enrollment and biannually
Number of subjects: 750
Study 33848258 — intervention group
Group type: EXPERIMENTAL
Intervention: Health care utilization data collected at follow-up
Number of subjects: 750
Study 33848258 — intervention group
Group type: EXPERIMENTAL
Intervention: Survival data collected throughout the study
Number of subjects: 750
Study 33848277 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound attenuation parameter (UAP)
Number of subjects: 237
Study 33848277 — intervention group
Group type: EXPERIMENTAL
Intervention: Liver stiffness measurement (LSM)
Number of subjects: 237
Study 33848277 — intervention group
Group type: EXPERIMENTAL
Intervention: FibroTouch examination
Number of subjects: 237
Study 33848277 — intervention group
Group type: EXPERIMENTAL
Intervention: FibroTouch UAP
Number of subjects: 237
Study 33849042 — intervention group
Group type: EXPERIMENTAL
Intervention: Flying intervention team model
Number of subjects: 2000000
Study 33849042 — intervention group
Group type: COMPARATOR
Intervention: Mothership model
Number of subjects: 2000000
Study 33849042 — intervention group
Group type: COMPARATOR
Intervention: Drip-and-ship model
Number of subjects: 2000000
Study 33849298 — intervention group
Group type: EXPERIMENTAL
Intervention: Navitoclax plus docetaxel
Number of subjects: 0
Study 33849466 — intervention group
Group type: EXPERIMENTAL
Intervention: Trifocal diffractive intraocular lens (IOL)
Number of subjects: 36
Study 33849560 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative computed tomography angiography (CT-angiography)
Number of subjects: 94
Study 33849560 — intervention group
Group type: COMPARATOR
Intervention: Registry data
Number of subjects: 94
Study 33849562 — intervention group
Group type: EXPERIMENTAL
Intervention: Time-restricted feeding (TRF) for 5 weeks
Number of subjects: 15
Study 33849625 — intervention group
Group type: EXPERIMENTAL
Intervention: No treatment limitations
Number of subjects: 2186
Study 33849625 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment limitations
Number of subjects: 2186
Study 33849625 — intervention group
Group type: COMPARATOR
Intervention: Patients without treatment limitations
Number of subjects: 2186
Study 33849625 — intervention group
Group type: COMPARATOR
Intervention: Patients that died post ICU discharge
Number of subjects: 2186
Study 33849625 — intervention group
Group type: COMPARATOR
Intervention: Patients with treatment limitations
Number of subjects: 2186
Study 33849855 — intervention group
Group type: EXPERIMENTAL
Intervention: MyPal digital health platform (ePRO-based functionalities via mobile applications)
Number of subjects: 100
Study 33849937 — intervention group
Group type: EXPERIMENTAL
Intervention: Mail order pharmacy use during shelter-in-place policy
Number of subjects: 0
Study 33849937 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 33850048 — intervention group
Group type: EXPERIMENTAL
Intervention: Holistic ultrasound approach for extubation failure
Number of subjects: 83
Study 33850048 — intervention group
Group type: EXPERIMENTAL
Intervention: Diaphragm thickening fraction with cutoff value of < 30%
Number of subjects: 83
Study 33851120 — intervention group
Group type: EXPERIMENTAL
Intervention: Arteriovenous Graft (AVG)
Number of subjects: 36
Study 33851120 — intervention group
Group type: EXPERIMENTAL
Intervention: Arteriovenous Fistula (AVF)
Number of subjects: 36
Study 33851120 — intervention group
Group type: COMPARATOR
Intervention: Control (not applicable)
Number of subjects: 36
Study 33851199 — intervention group
Group type: EXPERIMENTAL
Intervention: Food receipt paradigm
Number of subjects: 270
Study 33851199 — intervention group
Group type: EXPERIMENTAL
Intervention: Food picture paradigm
Number of subjects: 270
Study 33851199 — intervention group
Group type: EXPERIMENTAL
Intervention: Monetary reward paradigm
Number of subjects: 270
Study 33851199 — intervention group
Group type: EXPERIMENTAL
Intervention: Thin female model picture paradigm
Number of subjects: 270
Study 33851199 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual processing regions in Studies 3 and 4
Number of subjects: 270
Study 33851388 — intervention group
Group type: EXPERIMENTAL
Intervention: FXIII activity <70%
Number of subjects: 97
Study 33851388 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical patients and ICU patients
Number of subjects: 97
Study 33851388 — intervention group
Group type: EXPERIMENTAL
Intervention: Low FXIII activity
Number of subjects: 97
Study 33851388 — intervention group
Group type: EXPERIMENTAL
Intervention: Hemostatic level of FXIII
Number of subjects: 97
Study 33851429 — intervention group
Group type: EXPERIMENTAL
Intervention: Dopamine agonists (cabergoline, quinagolide, bromocriptine)
Number of subjects: 3171
Study 33851429 — intervention group
Group type: COMPARATOR
Intervention: Dopamine agonists
Number of subjects: 3171
Study 33851429 — intervention group
Group type: EXPERIMENTAL
Intervention: Dopamine agonists plus co-intervention (hydroxyethyl starch, human albumin, or coasting)
Number of subjects: 3171
Study 33851429 — intervention group
Group type: COMPARATOR
Intervention: Dopamine agonists plus co-intervention
Number of subjects: 3171
Study 33851429 — intervention group
Group type: COMPARATOR
Intervention: Cabergoline
Number of subjects: 3171
Study 33851477 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxycycline 100 mg p.o. b.i.d. for 14 days followed by imiquimod 5% cream topically to the most clinically active lesions 3 days a week for 28 days
Number of subjects: 2
Study 33852104 — intervention group
Group type: EXPERIMENTAL
Intervention: LY3022855 100 mg QW with durvalumab 750 mg Q2W
Number of subjects: 72
Study 33852104 — intervention group
Group type: EXPERIMENTAL
Intervention: LY3022855 50 or 100 mg QW with tremelimumab 75/225/750 mg Q4W
Number of subjects: 72
Study 33852104 — intervention group
Group type: EXPERIMENTAL
Intervention: LY3022855 25/50/75/100 mg QW with durvalumab 750 mg Q2W
Number of subjects: 72
Study 33852135 — intervention group
Group type: EXPERIMENTAL
Intervention: Sunitinib
Number of subjects: 65
Study 33852135 — intervention group
Group type: EXPERIMENTAL
Intervention: SU012662
Number of subjects: 65
Study 33852146 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose interleukin-2 (IL-2) treatment
Number of subjects: 18
Study 33852450 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunoglobulin A anti-tissue transglutaminase at the assay referenced upper limit of normal (30CU)
Number of subjects: 2353
Study 33852450 — intervention group
Group type: COMPARATOR
Intervention: Thresholds extrapolated from the general population for the diagnostic evaluation of celiac disease
Number of subjects: 2353
Study 33852969 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrical uterine myography
Number of subjects: 110
Study 33852969 — intervention group
Group type: COMPARATOR
Intervention: Tocodynamometry
Number of subjects: 110
Study 33852969 — intervention group
Group type: COMPARATOR
Intervention: Intrauterine catheter
Number of subjects: 110
Study 33853139 — intervention group
Group type: EXPERIMENTAL
Intervention: LATERA implant alone
Number of subjects: 277
Study 33853139 — intervention group
Group type: EXPERIMENTAL
Intervention: LATERA implant + ITR
Number of subjects: 277
Study 33853139 — intervention group
Group type: EXPERIMENTAL
Intervention: LATERA implant + septoplasty + ITR
Number of subjects: 277
Study 33853394 — intervention group
Group type: EXPERIMENTAL
Intervention: Caregivers reporting anxiety symptoms
Number of subjects: 34
Study 33853394 — intervention group
Group type: EXPERIMENTAL
Intervention: Caregivers during COVID-19
Number of subjects: 34
Study 33853608 — intervention group
Group type: EXPERIMENTAL
Intervention: Off-the-shelf active video games
Number of subjects: 15
Study 33853608 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-paced custom active video games
Number of subjects: 15
Study 33853608 — intervention group
Group type: EXPERIMENTAL
Intervention: Custom active video games
Number of subjects: 15
Study 33853608 — intervention group
Group type: COMPARATOR
Intervention: Standard of care stepping activities
Number of subjects: 15
Study 33853608 — intervention group
Group type: EXPERIMENTAL
Intervention: Game-paced custom active video games
Number of subjects: 15
Study 33853614 — intervention group
Group type: EXPERIMENTAL
Intervention: SUPER intervention (combining robotics, virtual reality activities, and neuromuscular electrical stimulation)
Number of subjects: 28
Study 33853614 — intervention group
Group type: EXPERIMENTAL
Intervention: Robotic-rehabilitation intervention focusing on elbow and shoulder movements (shoulder group; n=18)
Number of subjects: 28
Study 33853614 — intervention group
Group type: EXPERIMENTAL
Intervention: EMG-triggered NMES in addition to robot therapy (hand group; n=10)
Number of subjects: 28
Study 33854019 — intervention group
Group type: EXPERIMENTAL
Intervention: Extracorporeal Carbon Dioxide Removal
Number of subjects: 0
Study 33854019 — intervention group
Group type: COMPARATOR
Intervention: Extracorporeal Membrane Oxygenation
Number of subjects: 0
Study 33854317 — intervention group
Group type: EXPERIMENTAL
Intervention: Cariprazine (1.5-6 mg/d)
Number of subjects: 2048
Study 33854439 — intervention group
Group type: EXPERIMENTAL
Intervention: Maximum Electrically Induced Contraction (MEIC) in supine with knee flexion of 60° (SUP60)
Number of subjects: 20
Study 33854439 — intervention group
Group type: EXPERIMENTAL
Intervention: Maximum Electrically Induced Contraction (MEIC) in seated with knee flexion of 60° (SIT60)
Number of subjects: 20
Study 33854439 — intervention group
Group type: EXPERIMENTAL
Intervention: Maximum Electrically Induced Contraction (MEIC) in supine with knee flexion of 20° (SUP20)
Number of subjects: 20
Study 33854439 — intervention group
Group type: EXPERIMENTAL
Intervention: Maximum Electrically Induced Contraction (MEIC) in seated with knee flexion of 20° (SIT20)
Number of subjects: 20
Study 33854439 — intervention group
Group type: EXPERIMENTAL
Intervention: Current efficiency (MEIC/maximum tolerated current amplitude)
Number of subjects: 20
Study 33854439 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasonography of the quadriceps femoris (QF)
Number of subjects: 20
Study 33854439 — intervention group
Group type: EXPERIMENTAL
Intervention: Tendon-aponeurosis complex (TAC) displacement
Number of subjects: 20
Study 33854484 — intervention group
Group type: COMPARATOR
Intervention: Semaglutide (once-weekly subcutaneously)
Number of subjects: 0
Study 33854484 — intervention group
Group type: COMPARATOR
Intervention: Semaglutide (once-daily orally)
Number of subjects: 0
Study 33854484 — intervention group
Group type: COMPARATOR
Intervention: Oral semaglutide
Number of subjects: 0
Study 33854566 — intervention group
Group type: EXPERIMENTAL
Intervention: FOLFIRI/bevacizumab
Number of subjects: 0
Study 33854566 — intervention group
Group type: COMPARATOR
Intervention: FOLFIRI/aflibercept
Number of subjects: 0
Study 33854572 — intervention group
Group type: EXPERIMENTAL
Intervention: Certolizumab pegol (CZP) 400 mg at weeks 0, 2, and 4, then 200 mg every 2 weeks to week 96
Number of subjects: 115
Study 33854746 — intervention group
Group type: EXPERIMENTAL
Intervention: Modern therapeutic approaches for CTEPH (specific interventions not detailed in the abstract)
Number of subjects: 516
Study 33854746 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of two or three methods in treatment of CTEPH (specific methods not detailed in the abstract)
Number of subjects: 516
Study 33855205 — intervention group
Group type: EXPERIMENTAL
Intervention: Single autoantibody (n = 30)
Number of subjects: 76